Zoetis Announces Committee For Veterinary Medicinal Products Of The EMA Has Adopted A Positive Opinion Recommending The Granting Of Marketing Authorization For Lenivia For The Reduction Of Pain Associated With Osteoarthritis In Dogs

Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Based on the CVMP's positive opinion, the European Commission is expected to issue a decision during the fourth quarter of 2025, and Zoetis anticipates making Lenivia commercially available in the European Union in 2026.

If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of science and research, with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced increased mobility and decreased pain after one injection.

Significance of OA Pain

Osteoarthritis is a common, chronic and progressive joint disease characterized by the inflammation and breakdown of joints, resulting in pain and mobility issues. Although the disease cannot be cured, much can be done to reduce the associated pain, leading to improved quality of life. Nearly 40 percent of dogs of any age or size may be affected by OA pain1, 2, and chronic pain can negatively impact dogs' movement, sleep, behavior and social relationships3.